MDI THERAPEUTICS INC

Novi, MI · Founded 2015 · Biotech · Private

Novel small-molecule and biologic therapeutics targeting fibrosis and fibroproliferative diseases

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · mditherapeutics.com

Sector: Biotech
Headquarters: Novi, MI
Founded: 2015
Latest Form D: $1.7M, Mar 2022
Total capital: $9M

Federal grants: $7.3M; 10 awards · 2018–2023; Rank in peer group#263 of 514
Private capital raised: $1.7M; 2 Form D · last Mar 2022; 56 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Mar 2023Federal grantHealth and Human S · Phase II · Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis$709K
Mar 2022Private capital raisedForm D · SEC · 2nd filing$1.7M
Mar 2022Federal grantHealth and Human S · Phase II · Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis$1.7M
Mar 2022Federal grantHealth and Human S · Phase II · Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis$1M
Aug 2020Federal grantHealth and Human S · Phase II · Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$747K
Sep 2019Federal grantHealth and Human S · Phase II · Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$1.5M
Aug 2019Federal grantHealth and Human S · Phase II · Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$747K
Feb 2018Offering registeredForm D · SEC · 1st filing$1.6M

Show 4 earlier federal awards

Jan 2019Federal grantHealth and Human S · Phase I · Preclinical development of a first in class therapeutic for treatingidiopathic pulmonary fibrosis$225K
Dec 2018Federal grantHealth and Human S · Phase I · Preclinical development of a first in class therapeutic for treating idiopathic pulmonary fibrosis$225K
Aug 2018Federal grantHealth and Human S · Phase I · Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$217K
Jul 2018Federal grantHealth and Human S · Phase I · Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis$217K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Daniel A LawrenceExecutive OfficerNamed in SEC Form D filings
Daniel Lawrence, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
David C GinsburgDirectorNamed in SEC Form D filings
Duane E DayExecutive OfficerNamed in SEC Form D filings
Grazia C PiizziDirectorNamed in SEC Form D filings
Stephen C BenoitExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Theratome Bio, Inc.Similar federal contract value in Biotech · null in contracts
Blue Oak Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
SHIFA BIOMEDICAL CORPORATIONSimilar federal contract value in Biotech · null in contracts
NOVILYTIC, LLCSimilar federal contract value in Biotech · null in contracts
OPTIKIRA, LLCSimilar federal contract value in Biotech · null in contracts
AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.